Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|174-181

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 174-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

By Prichard Mark   Harris Thomas   Williams Michael E   Densmore John J  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 983-995

Informa Healthcare

Access to resources Recommend Favorite

mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma

By  

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 945-954

Bentham Science Publishers

Access to resources Recommend Favorite

Brentuximab Vedotin

By  

Drugs in R&D, Vol. 11, Iss. 1, 2011-03 ,pp. : 85-95

Adis International

Access to resources Recommend Favorite

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

By Ansell Stephen M  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 99-105

Informa Healthcare

Access to resources Recommend Favorite

Lenalidomide offers effective treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite